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California Policy Recommendations for
Realizing the Promise of Medication Abortion:
How the COVID-19 Public Health Emergency
Offers a Unique Lens for Catalyzing Change
KERRI PINCHUK*

Abstract: While the new composition of the United States Supreme Court
has raised speculation about the fate of Roe v. Wade, for millions in America
the promise of a patient’s right to choose an abortion is already a distant
illusion.** Decades of work by anti-abortion policymakers has resulted in
prohibitive state and federal funding restrictions and widespread clinic
closures. But clinicians, advocates, and researchers are optimistic about one
way to expand access: medication abortion. Known colloquially as “the
abortion pill,” medication abortion is poised to significantly increase access
for patients everywhere, and particularly for low-income patients and those
who live in rural areas far from hospitals and clinics.
One of the biggest barriers to medication abortion today is a stringent
set of FDA regulations implemented under the guise of patient safety
protocols, which evidence suggests are not only medically unnecessary but
politically motivated. While researchers and advocates have been working to
lift these restrictions for years, the unprecedented COVID-19 pandemic has
provided unique circumstances for studying how access would be affected if
the restrictions were to be permanently lifted.
In California, there are three legislative steps that the state can take to
* Juris Doctor Candidate, University of California, Hastings College of the Law. Thanks
to Professor Steven Bonorris for his guidance and Jennifer Dunn for her mentorship. Special
thanks to Lisa Matsubara for her time and critical input. All identifiers used in this note are
taken directly from their sources (e.g. studies, direct quotes, etc.) and are not the author’s
preference.
** Many abortion rights advocates believe that the election of pro-choice President Joe
Biden in November 2020 presents opportunities for codifying protections of a patient’s right
to choose. Given intense conservative opposition to abortion protections in the current
Congress, such executive action would undoubtedly give way to legal action. To avoid the
myriad hypothetical situations that could arise, this note will not address those potential
avenues and will instead focus on the national legislative and judicial status quo.
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ensure that Californians have continued access to abortion as guaranteed by
the State Constitution, and to expand access to low-income patients and
patients in rural areas. First, the State should support the creation of a
centralized database for collecting medication abortion data from across the
state while restrictions were lifted. Second, the State should remove the dualultrasound requirement for Medi-Cal reimbursement. Third, the State should
close a loophole in current policy that prevents minors from obtaining
medication abortion via telehealth.
It is clear that politicization of reproductive rights will remain a fixture
of civil discourse in America for years to come. At the same time, advances
in telehealth technology have already provided a glimpse into a future where
patients are able to access the reproductive care they need. As a national
leader in reproductive justice efforts, California has the opportunity to create
lasting impact by exploring efforts to expand access to key patient
populations and prepare for a future of true reproductive justice.
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I. INTRODUCTION
Medication abortion (MAB), commonly referred to as the “abortion pill,”
is a safe and effective method of self-managed abortion.1 MAB has become
an increasingly popular choice among patients seeking both therapeutic and
elective abortions. More than four million women have used MAB to end an
early pregnancy in the United States.2 Now the most commonly used method
of abortion for pregnancies up to ten weeks’ gestation, MAB accounted for
sixty percent of all such abortions in the United States in 2017.3 Patients opt
for MAB over surgical procedures for a variety of reasons, chief among them
the privacy, comfort, and convenience of passing a pregnancy at home, which
often comes with the support of friends or family.
In addition to these patient benefits, clinicians, advocates, and experts
across the country celebrate MAB for its power to expand access to lowincome patients and patients living in rural areas.4 But this power remains
largely inhibited by federal dispensation requirements, costly components of
care delivery, low reimbursement rates for providers, and, importantly,
obstruction by anti-abortion politicians. Among many other gaps in the U.S.
health care system, these barriers to MAB provision have been highlighted
by the COVID-19 public health emergency.
MAB involves a pill regimen of two medications, mifepristone (brand
name Mifeprex) and misoprostol (brand name Cytotec, among others),
prescribed by a clinician and ingested successively.5 First, mifepristone
blocks the body’s production of progesterone, the hormone necessary for a
pregnancy to develop, effectively terminating the pregnancy.6 Taken up to
forty-eight hours later, misoprostol then causes uterine contractions and
cervical dilation, ultimately expelling the contents of the uterus.7 Federal law
requires that the pills be dispensed to patients by a clinician, but depending
on state laws, ingestion takes place in the presence of the prescribing clinician
1

Megan Donovan, Medication Abortion and the Changing Abortion Landscape,
GUTTMACHER INST., https://www.guttmacher.org/article/2019/09/medication-abortion-andchanging-abortion-landscape (last visited Mar. 8, 2021).
2 Extrapolated from the FDA’s “Mifepristone U.S. Post-Marketing Adverse Events
Summary through 12/31/2018,” which found that 3.7 million women had used mifepristone
to end a pregnancy in the United States through the end of 2018. Mifepristone U.S. PostMarketing
Adverse
Events
Summary
through
12/31/2018,
FDA,
https://www.fda.gov/media/112118/download (last visited Mar. 9, 2021).
3 Donovan, supra note 1.
4
Id.
5
The
Abortion
Pill,
PLANNED
PARENTHOOD,
https://www.plannedparenthood.org/learn/abortion/the-abortion-pill (last visited Mar. 13,
2021).
6 Id.
7 Id.
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or at a time and location of the patient’s choosing.8,9 In California, the patient
may ingest the pills at a time and location of their choice.10 For the purposes
of this note, I will focus almost exclusively on mifepristone because it is
heavily restricted by the United States Food and Drug Administration
(FDA).11 Misoprostol is commonly prescribed for uses other than MAB,
including inducing labor and ripening the cervix before medical procedures,
and is thus far less heavily restricted.12
The COVID-19 public health emergency has highlighted disparities and
opportunities for increasing access to MAB in California. The disparities are
evident in reduced access for vulnerable patient populations due to increased
financial hardship and diminished access to care. The opportunities lie in the
fact that the temporarily relaxed in-person restrictions for MAB provisions
created a window for understanding what the future of MAB could look like.
This note considers the current landscape of MAB and ultimately provides
three recommendations for actions California can take to ensure maximum
and continuous access to MAB beyond the COVID-19 public health
emergency: first, the State should foster collection and analysis of no-touch
MAB and TeleMAB (MAB prescribed via telehealth) data collected while
the FDA’s in-person requirements were lifted.13 Second, the State should
remove the costly dual-ultrasound requirement for Medi-Cal
reimbursement.14 Third, the State should close a loophole in current
telehealth policy that would prevent minors from accessing TeleMAB
services.15
This note begins by providing an introduction to the FDA’s restrictions
of MAB and its arguably politically motivated restrictions at the federal
level.16 It also traces a brief history of MAB access during the COVID-19
pandemic, setting the stage for understanding how the temporary removal of
8

Mifeprex (mifepristone) Information, U.S. FOOD & DRUG ADMIN.,
https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-andproviders/mifeprex-mifepristone-information (last visited Mar. 8, 2021) [hereinafter FDA,
Mifepristone Information].
9 PLANNED PARENTHOOD, supra note 5; The Availability and Use of Medication Abortion,
KAISER FAM. FOUND. (June 8, 2020), https://www.kff.org/womens-health-policy/factsheet/the-availability-and-use-of-medication-abortion/.
10 State Laws and Policies: Medication Abortion, GUTTMACHER INST. (updated Mar. 1,
2021), https://www.guttmacher.org/state-policy/explore/medication-abortion (listing states
that require physicians to administer medication abortion and states that require the clinician
to be physically present when the medication is administered).
11 See FDA, Mifepristone Information, supra note 8.
12
Rebecca Allen & Barbara M. O’Brien, Uses of Misoprostol in Obstetrics and
Gynecology, REV. OBSTETRICS & GYNECOLOGY, Summer 2009, at 159.
13 See infra section II.C.
14 See infra section III.C.
15 See infra section IV.B.
16 See infra section II.A.
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in-person requirements may have affected access for Californians.17 Next,
this note discusses restrictions on public funding at the federal and state level
that decrease access for low-income and rural patients—and specifically,
how the impacts of California’s low reimbursement rates can be mitigated by
removing the ultrasound requirement for MAB.18 Finally, this note finishes
by proposing a solution for a loophole currently preventing minors from
accessing TeleMAB in California.19

II. BACKGROUND: THE FDA’S REGULATION OF
MIFEPRISTONE AND THE EFFECTS OF COVID-19
A major barrier to MAB access across the country is a set of federal
restrictions the FDA places on the prescription and dispensation of
mifepristone. A true expansion of MAB access necessitates the permanent
removal of these restrictions. While many states place additional restrictions
on MAB, California has few and is thus an ideal setting for understanding
gaps and opportunities that exist in the push for expanding access. COVID19 catalyzed a chain of events that allows for this analysis.
A. The FDA’s REMS for Mifepristone are Motivated by Politics,
Not Patient Safety
As mentioned above, MAB involves a pill regimen of two medications:
mifepristone and misoprostol, ingested successively.20
This section
examines each of the Risk Evaluation and Mitigation Strategy (REMS)
restrictions that the FDA imposes on mifepristone to underscore expert
assessments that they are not medically necessary. According to the FDA,
REMS are designed to help reduce the “occurrence or severity of a particular
serious adverse event.”21 The below exploration is based largely on the
substance of plaintiffs’ argument in Chelius v. Azar, an ongoing federal
lawsuit brought on behalf of a Hawai‘i doctor and several professional health
care organizations.22 Chelius challenges the constitutionality of the REMS
as placing significant burdens, with no medical basis, on women seeking

17

See infra section II.B.
See infra section III.A-C.
19
See infra section IV.A-B.
20 PLANNED PARENTHOOD, supra note 5.
21 Frequently Asked Questions About REMS, U.S. FOOD & DRUG A DMIN. (Jan. 26, 2018),
https://www.fda.gov/drugs/risk-evaluation-and-mitigation-strategies-rems/frequently-askedquestions-faqs-about-rems.
22 Complaint at 19, Chelius v. Wright, 2017 WL 4401999 (D.Hawai‘i).
18
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medication abortions.23 The plaintiffs’ case relies heavily on data from the
FDA’s own 2016 medical review of Mifeprex.24 Abortion advocates hope
that the outcome of this case will lead to a permanent removal of the REMS
restrictions.
In 2000, the FDA approved Mifeprex for use up to forty-nine days into a
pregnancy (today it is approved for up to seventy days).25 Despite a
substantial safety record of data from U.S. trials and European markets, the
FDA assigned three significant REMS restrictions to the drug as a condition
of approval: explained in detail below, two restrictions require a patient to
present in person for prescription and dispensation, and the other requires
providers to submit specific documentation to the drug manufacturer.26 After
the FDA determines that a REMS is necessary and specifies the requirements,
the drug manufacturer is then responsible for developing and implementing
the program.27 The FDA may later release or lift certain components of a
REMS if it determines that the extra measures are no longer necessary to
ensure a medication’s benefits outweigh its risks.28
The most burdensome types of REMS are “Elements to Assure Safe Use”
(ETASU), which the FDA may impose on a drug that has been shown to be
effective only if it is associated with a “serious adverse drug experience”
(defined as resulting in death, immediate risk of death, inpatient
hospitalization, a persistent or significant incapacity or substantial disruption
of the ability to conduct normal life functions, or a congenital anomaly or
birth defect).29,30 In 2017, of the nearly 1,800 FDA-approved prescription
drugs and therapeutic biologic active ingredients on the U.S. market, only
seventy-three were subject to a REMS—and just forty-three were subject to
a REMS with ETASU.31 Importantly, ETASU are not to be “unduly
burdensome on patient access to the drug, considering in particular …
patients who have difficulty accessing health care (such as patients in rural

23 Complaint at 19, Chelius v. Wright, 2017 WL 4401999 (D.Hawai‘i). When the
complaint was filed in 2017, it named then-Acting Secretary of Department of Health and
Human Services Don Wright. Later stages of litigation name Secretary Alex Azar. Id.
24 Id. (citing U.S. FOOD & DRUG ADMIN., CTR. FOR DRUG EVALUATION & RSCH., App.
No. 020687Orig1s020, Mifeprex Medical Review(s) (Mar. 29, 2016), available at
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/020687Orig1s020MedR.pdf (last
visited Mar. 10, 2021)).
25 FDA, Mifepristone Information, supra note 8.
26 Complaint, Chelius v. Wright, 2017 WL 4401999 (D.Hawai‘i).
27
Id.
28 Id.
29 Complaint at 18-19, Am. Coll. of Obstetricians & Gynecologists v. U.S. Food & Drug
Admin., 2020 WL 2771735 (D.Md.).
30 21 U.S.C.A. § 355-1.
31 Complaint at 4, Chelius v. Wright, 2017 WL 4401999 (D.Hawai‘i).
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or medically underserved areas).”32 In California, the Medi-Cal Provider
Manual mandates that providers adhere to the enumerated FDA REMS in
order to bill for a bundled payment reimbursement for MAB.33 Considering
that Medi-Cal covers about half of abortions in California, we know that the
Mifeprex REMS with ETASU directly impact many low-income patients
across the state.34 California adults qualify for Medi-Cal if their income is
up to 138% of the federal poverty level, or $17,609 in 2020.35
The three ETASU assigned to Mifeprex are as follows:
• ETASU A: Clinicians prescribing mifepristone must send a
prescriber agreement form to the drug distributor attesting to
their clinical abilities, agreeing to comply with certain reporting
requirements, and agreeing to comply with other REMS
elements.36
• ETASU C: Mifepristone may be dispensed only in a hospital,
clinic, or medical office—not in retail pharmacies—by or under
the supervision of a certified prescriber.37
• ETASU D: The prescriber and patient must, in person, review
and sign a special Patient Agreement Form containing
information regarding the mifepristone.38
According to experts, the FDA’s decision to place these stringent
regulations on Mifeprex was “highly unusual.”39 Nearly twenty years of data
provides Mifeprex with a record of up to ninety-nine percent efficacy and
exceptional safety.40 In the first fifteen years of U.S. post-marketing data on
Mifeprex, there were seventeen reported associated deaths out of 2.5 million
uses—an associated fatality rate of 0.00068%.41 Further, in 2016 the FDA
determined that because adverse events associated with mifepristone are so
32

21 U.S.C.A. § 355-1.
Medi-Cal Provider Manual for abortion (abort) at 7, CALIF. DEP’T OF HEALTH CARE
SERVS. (updated Sept. 16, 2020), available at https://filesaccepttest.medical.ca.gov/pubsdoco/Publications/masters-MTP/Part2/abort.pdf
[hereinafter
Medi-Cal
Provider Manual].
34 Nicole E. Johns, Diana Greene Foster & Ushma D. Upadhyay, Distance traveled for
Medicaid-covered abortion care in California, 17 BMC HEALTH SERV. RES. 287 (2017) (citing
CALIF. DEP’T OF HEALTH CARE SERVS., Medi-Cal funded induced abortions, 2010).
35 Do You Qualify for Medi-Cal Benefits?, CALIF. DEP’T OF HEALTH CARE SERVS. (May
5, 2020), https://www.dhcs.ca.gov/services/medi-cal/Pages/DoYouQualifyForMedi-Cal.aspx.
36 21 U.S.C.A. § 355-1(f)(3)(A).
37 21 U.S.C.A. § 355-1(f)(3)(C).
38 21 U.S.C.A. § 355-1(f)(3)(D).
39
Complaint at 20, Chelius v. Wright, 2017 WL 4401999 (D.Hawai‘i).
40 U.S. FOOD & DRUG ADMIN., CTR. FOR DRUG EVALUATION & RSCH., App. No.
020687Orig1s020, Mifeprex Medical Review(s) at 23 (Mar. 29, 2016), available at
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/020687Orig1s020MedR.pdf (last
visited Mar. 10, 2021) [hereinafter FDA, Mifeprex Medical Review].
41 Id. at 82-83.
33
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rare, it was appropriate for the manufacturer to cease reporting adverse events
other than death.42 The FDA has acknowledged that “[t]here is no
information that use of Mifeprex and misoprostol caused the ‘very small
number’ of deaths from infection. Rather… [CDC findings suggest]
pregnancy itself was the ‘critical risk factor’ [in] cases of fatal infection.”43
Ironically, given the United States’ dismal maternal mortality rate, the
associated fatality risk of carrying a pregnancy to term is about fourteen times
greater than the risk of using Mifeprex.44
By way of comparison, mifepristone-based drug Korlym is often
prescribed as treatment for Cushing syndrome, a disease caused by high
levels of the hormone cortisol.45,46 Even though Korlym is taken daily, at
home, in higher doses, and with higher rates of adverse events than Mifeprex,
Korlym is not subject to a REMS.47 In a final comparison, the fatality rate
associated with phosphodiesterase type five inhibitors for the treatment of
erectile dysfunction (e.g., Viagra) is estimated at 0.0026%, roughly four
times that of Mifeprex.48 Yet, prescription Viagra is not subject to a REMS.49
These statistics, considered in light of brazen and persistent calls by antiabortion politicians to ban MAB specifically, suggest that the REMS are
motivated not by concern for patient safety but by political will.50
Provider certification like the kind required by ETASU A is not required
for professionals to dispense many other drugs, some of which include “black
box” warnings about their risks.51 Moreover, the prescriber agreement forces
abortion providers to self-identify to an entity that is routinely inspected by

42

Complaint at 35, Chelius v. Wright, 2017 WL 4401999 (D.Hawai‘i).
Id. at 38. Of the seventeen reported deaths in women who had taken Mifeprex, five
involved events unrelated to the medication, such as narcotic overdose or suspected homicide.
Id.
44 Id. at 3.
45 FDA, Mifeprex Medical Review, supra note 40, at 10.
46 “Cushing syndrome occurs when [a] body is exposed to high levels of the hormone
cortisol
for
a
long
time.”
Cushing
Syndrome,
MAYO
CLINIC,
https://www.mayoclinic.org/diseases-conditions/cushing-syndrome/symptoms-causes/syc20351310.
47 FDA, Mifeprex Medical Review, supra note 40, at 10.
48 Complaint at 38, Chelius v. Wright, 2017 WL 4401999 (D.Hawai‘i).
49 Id. at 35.
50 William Cummings, 'Pregnancy is not a life-threatening illness': Ted Cruz takes heat
in
call
to
ban
abortion
pill,
USA
TODAY
(Sept.
3,
2020),
https://www.usatoday.com/story/news/politics/2020/09/03/ted-cruz-pregnancy-not-lifethreatening-abortion-bill-ban/5700978002/.
51 A “black box warning” or “boxed warning” appears on a prescription drug’s label and
is designed to call attention to serious or life-threatening risks. Consumer Health Information,
A Guide to Drug Safety Terms at FDA at 2, U.S. FOOD & DRUG ADMIN. (Nov. 2012),
https://www.fda.gov/downloads/forconsumers/consumerupdates/ucm107976.pdf.
43
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the federal government.52 Considering some policymakers’ politicization of
abortion rights and the violence routinely perpetrated against abortion
providers, this requirement effectively weeds out clinicians who may be
uncomfortable publicly identifying as abortion providers—especially in
abortion-hostile regions.53 With fewer providers willing to stock the
medication, there are fewer opportunities for patients to access MAB in
places where state-level restrictions already pose significant barriers.
Particularly resonant for the goals of this note, the in-person dispensation
requirement (ETASU C) serves no medical purpose. Of the three ETASU
assigned to Mifeprex, this requirement is among the rarer ETASU assigned
to a drug and provides the biggest barrier to access for patients. Out of more
than 20,000 drugs regulated by the FDA—including self-administered
injectables, opioids, and other drugs with high potential for danger or
abuse— Mifeprex is the only one that patients must receive in person at a
hospital, clinic, or medical office, yet may self-administer unsupervised at a
location of their choice.54 Experts agree that the dispensing location has no
effect on the safety or efficacy of the medication.55 As the Mifeprex label
makes clear, the medication’s effects do not begin until hours after ingestion:
“most women will expel the pregnancy within 2 to 24 hours of taking
misoprostol [the second drug in the regimen].”56 This amounts to a total of
twenty-six to seventy-two hours after taking mifepristone; and for patients in
states with mandatory waiting periods for abortion care, this could mean up
to four days after the patient first presents to a clinician. It is highly unlikely
that a patient will still be under the direct supervision of her certified
prescriber if she experiences adverse effects at that time. In short, “there is
no relationship between where a woman is standing when she receives the
Mifeprex pill and any potential risk of infection or bleeding.”57 There is no

52

Complaint at 27, Chelius v. Wright, 2017 WL 4401999 (D.Hawai‘i) (citing to Letter
from SFP, et al., to Stephen Ostroff, M.D., Robert M. Califf, M.D., & Janet Woodcock, M.D.
(Feb. 4, 2016)).
53 Id. In 2014, one in five U.S. health care facilities that provide abortions experienced
“severe violence” such as blockades, invasions, bombings, arsons, chemical attacks, physical
violence, stalking, gunfire, bomb threats, arson threats, or death threats.
54 Complaint at 3, Am. Coll. of Obstetricians & Gynecologists v. U.S. Food & Drug
Admin., 2020 WL 2771735 (D.Md.).
55 Complaint at 41, Chelius v. Wright, 2017 WL 4401999 (D.Hawai‘i).
56 Mifeprex
(Mifepristone)
Tablets
Label,
available
at
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020687s020lbl.pdf (last visited
Mar. 13, 2021). Mifeprex labeling is a rigorous part of the FDA approval process. Thanks to
persuasion from doctors and professional medical associations—including some plaintiffs in
the Chelius case—the FDA has made significant updates to the Mifeprex label over time that
more accurately communicate its uses.
57 Complaint at 37, Chelius v. Wright, 2017 WL 4401999 (D.Hawai‘i).
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evidence-based connection between in-person dispensation and patient
safety.
Similarly, regarding ETASU D, there is no data suggesting that a
patient’s location when signing a form has any effect on the safety or efficacy
of the medication—whether she is signing it in the physical presence of a
doctor or virtually via a telehealth visit. But more importantly, many
clinicians agree that the signing of the Patient Agreement form is altogether
duplicative, emotionally draining, and interferes with the patient-physician
relationship.58 Abortion patients already receive extensive counseling under
standard informed consent practices, they receive the FDA-regulated
Medication Guide for Mifeprex, and they are subject to additional counseling
practices that vary across states and individual clinics or hospitals.59 Adding
an additional layer of consultation via a Patient Agreement form is, again,
not medically necessary.
Finally, as with any substance regulated by the government, erecting
barriers to access cements the risk of desperate patients turning to sketchy
sources. While more research is needed to understand the scope of this issue,
we know that some patients obtain MAB drugs online from unlicensed
foreign sellers.60 These patients have no clinical supervision, have not
undergone a professional screening, and may not understand potential
contraindications resulting in true adverse reactions. These conditions set a
dangerous stage reminiscent of pre-Roe America, when desperate patients
resorting to unsafe methods of abortion resulted in an estimated 200 deaths
per year.61
Physicians and experts across the country, including at least one former
FDA administrator, agree that the outdated REMS should be lifted.62 The
American College of Obstetrics and Gynecologists (ACOG), the country’s
leading group of physicians providing health care for women, has urged
removal of the REMS on behalf of its 60,000 members.63 As of the time of

58 Telephone Interview with Mary Fjerstad, Clinician, on Nov. 11, 2020 (on file with
author).
59 Complaint at 28-30, Chelius v. Wright, 2017 WL 4401999 (D.Hawai‘i).
60 Gabriella Borter, U.S. states unsure how to halt online sales of abortion pills amid
clinic crackdown, REUTERS (June 27, 2019), https://www.reuters.com/article/us-usa-abortionpills/u-s-states-unsure-how-to-halt-online-sales-of-abortion-pills-amid-clinic-crackdownidUSKCN1TS1AB.
61 All Things Considered: What Abortion Was Like In The U.S. Before Roe v. Wade at
1:46, NPR (May 20, 2019), https://www.npr.org/2019/05/20/725139713/what-abortion-waslike-in-the-u-s-before-roe-v-wade.
62 Jane E. Henney & Helene D. Gayle, Time to Reevaluate U.S. Mifepristone Restrictions,
381 THE NEW ENGLAND J. OF MED. 597, 597-98 (2019).
63 Improving Access to Mifepristone for Reproductive Health Indications: Position
Statement, AM. COLL. OF OBSTETRICIANS & GYNECOLOGISTS (June 2018),

1 - CAPULONG_KING_RIES HRPLJ V18-1 (DO NOT DELETE)

276

HASTINGS RACE & POVERTY LAW JOURNAL

4/7/2021 1:05 AM

Vol. 18

this writing, the Biden-Harris Administration has signaled strong support for
reproductive rights expansion; however, the president has yet to nominate the
FDA commissioner who would ultimately make the call to remove the REMS
on mifepristone.64 A permanent removal of the REMS would not only reduce
barriers to access, but in some places would allow for completely remote
provision of TeleMAB. This is because while eighteen states explicitly
prohibit abortion via telehealth, other states, including California, have no
such restrictions.65 While TeleMAB is still in early days of study, researchers
and advocates feel confident in its promise to substantially reduce costs while
vastly increasing access. TeleMAB could remove many of the associated
costs, stressors, and inconveniences experienced by low-income and rural
abortion patients, such as traveling to a clinic, taking time off work, securing
childcare, and undergoing anesthesia.66
B. The COVID-19 Public Health Emergency and MAB
When the seriousness of the COVID-19 pandemic became evident to the
public in early 2020, the federal government and all fifty states declared some
level of public health emergency.67 As travel restrictions, social distancing
protocols, and decreased capacity at hospitals and clinics vastly hindered
health care delivery, an obvious means of expanding access to care was
through telehealth. Even as the Trump Administration downplayed the
seriousness of the pandemic, the Department of Health and Human Services
took historic action to expand telehealth services by relaxing federal privacy

https://www.acog.org/clinical-information/policy-and-position-statements/positionstatements/2018/improving-access-to-mifepristone-for-reproductive-health-indications.
64 See Sarah McCammon, Biden Administration Prepares To Overturn Trump Abortion
Rule, NPR (Jan. 21, 2021), https://www.npr.org/sections/president-biden-takesoffice/2021/01/21/959170860/biden-administration-prepares-to-overturn-trump-abortionrule; Laurie McGinley, Biden’s delay on naming FDA chief perturbs some experts, WASH.
POST (Feb. 11, 2021), https://www.washingtonpost.com/health/2021/02/11/biden-fdaappointment-covid/.
65 Melissa Jeltsen, Coronavirus Is Endangering Abortion Access. Telemedicine Could
Solve it., HUFF. POST (Mar. 20, 2020), https://www.huffpost.com/entry/medication-abortiontelemedicine_n_5e74ec23c5b6eab779472982.
66 See generally TelAbortion.org, GYNUITY HEALTH PROJECTS, https://telabortion.org/
(last visited Mar. 13, 2021).
67
Status of State COVID-19 Emergency Orders, NAT’L GOVERNORS ASS’N
https://www.nga.org/state-covid-19-emergency-orders/ (visited Jan. 23, 2021); Samuel
Wonacott, All 50 states have active declared emergencies related to the coronavirus
pandemic,
BALLOTPEDIA
NEWS
(July
29,
2020,
3:47
PM),
https://news.ballotpedia.org/2020/07/29/all-50-states-have-active-declared-emergenciesrelated-to-the-coronavirus-pandemic/.
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laws.68 In an effort to encourage the use of telehealth services, on April 3,
2020, California Governor Gavin Newsom issued an executive order
removing several obstacles to telehealth provision, including the relaxing of
requirements around signing telehealth consent forms.69
Meanwhile, clinicians and advocates witnessed growing challenges for
those seeking health care across the board: local lockdown mandates
compounded traditional barriers like financial strain and finding childcare;
showing up to facilities for in-person care exacerbated the risk of COVID-19
exposure; and, health risks associated with delays in care grew more dire by
the day. Even as at least eleven states seized the opportunity to put more
restrictions on abortion or ban it outright, advocates took critical steps to
ensure that abortion care would remain safe and accessible.70 In March 2020,
ACOG issued a statement acknowledging that dating a pregnancy based on
a patient’s last menstrual period (LMP) without ultrasound was acceptable
for MAB.71 In April 2020, leading physicians, researchers, and professional
organizations developed a “no-touch” or “no-test” protocol deemed not only
acceptable for MAB provision, but safe, effective, and commensurate with
the traditional standard of care.72
In May 2020, the American Civil Liberties Union (ACLU) filed suit on
behalf of ACOG to lift the FDA’s REMS requirements on mifepristone.73
Specifically, the ACLU alleged that the FDA’s continued enforcement of the
requirements to pick up the medication and sign specific forms in person
unnecessarily exposed patients and clinicians to heightened risk of exposure
to COVID-19 for no medical purpose, and that the in-person requirements
put their health and lives at risk.74 The plaintiffs also pointed out that the
FDA relaxed in-person requirements for other highly regulated drugs during
the pandemic, “to afford clinicians discretion to provide appropriate medical

68 Secretary Azar Announces Historic Expansion of Telehealth Access to Combat
COVID-19, U.S. DEP’T OF HEALTH & HUMAN SERVS. (Mar. 17, 2020),
https://www.hhs.gov/about/news/2020/03/17/secretary-azar-announces-historic-expansionof-telehealth-access-to-combat-covid-19.html.
69 Calif. Exec. Order No. N-43-20 (Apr. 3, 2020), https://www.gov.ca.gov/wpcontent/uploads/2020/04/4.3.20-EO- N-43-20-text.pdf.
70 These bans did not survive legal challenges but created confusion and fear among
patients.
71 COVID-19 FAQs for Obstetrician–Gynecologists, Gynecology, AM. COLL. OF
OBSTETRICIANS & GYNECOLOGISTS, https://www.acog.org/clinical-information/physicianfaqs/covid19-faqs-for-ob-gyns-gynecology (last visited Mar. 13, 2021).
72
Elizabeth G. Raymond et al., Commentary: No-test medication abortion: A sample
protocol for increasing access during a pandemic and beyond, 101 CONTRACEPTION 361, 36166 (2020).
73 Complaint, Am. Coll. of Obstetricians & Gynecologists v. U.S. Food & Drug Admin.,
472 F.Supp.3d 183 (D.Md. 2020), No. TDC-20-1320, 2020 WL 2771735.
74 Id. at 18-19.
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care under these emergency circumstances,” but not mifepristone.75 In a July
2020 decision, the U.S. District Court for the District of Maryland ruled for
ACOG in American College of Obstetricians and Gynecologists v. FDA,
representing a huge win for access.76 The court enjoined the FDA’s in-person
requirements for prescribing mifepristone for the duration of the public health
emergency.77
The federal injunction immediately impacted MAB provision across the
country in critical ways. Most importantly, the injunction allowed
mifepristone to be dispensed by mail or delivery service unless otherwise
restricted by state law.78 Though mifepristone still had to be prescribed by
or under the supervision of a certified health care provider as defined in the
REMS, mail-order pharmacies could serve as intermediaries, sparing patients
the in-person trips to their prescribing health care facility.79 Additionally,
patients were permitted to physically or electronically sign the Patient
Agreement form during a telehealth appointment and return the form
electronically or by mail; alternatively, a patient could give verbal consent to
the terms of the form during a telehealth session.80 The injunction was set to
apply for thirty days past the end of the national public health emergency.81
If there is a silver lining to the COVID-19 pandemic, it is that under the
injunction providers, researchers, and activists were able to administer MAB
with significant barriers removed. But this small win was short-lived. After
multiple unsuccessful attempts to stay the injunction, the Trump
Administration finally prevailed in a last-ditch appeal: on January 12, 2021,
in its first abortion-related decision since Justice Amy Coney-Barrett’s
confirmation, the United States Supreme Court re-imposed the in-person
dispensation and signature requirements.82 In a short concurrence, Chief
Justice John Roberts opined that the courts should defer to “politically
accountable entities” on decisions related to pandemic governance.83 In a
sharp dissent rebuking the Court’s decision, Justice Sonia Sotomayor pointed
out that a stay of a district court’s injunction has in the past been viewed as

75

Complaint at 27, Am. Coll. of Obstetricians & Gynecologists v. U.S. Food & Drug
Admin., 472 F.Supp.3d 183 (D.Md. 2020), No. TDC-20-1320, 2020 WL 2771735.
76 Order Clarifying July 13 Memorandum Opinion, Am. Coll. of Obstetricians &
Gynecologists v. U.S. Food & Drug Admin., No. TDC-20-1320, 2020 WL 8167535 (D. Md.
Aug. 19, 2020).
77 Id.
78 Id.
79
Id.
80 Id.
81 Id.
82 Food & Drug Admin. v. Am. Coll. of Obstetricians & Gynecologists, 141 S. Ct. 578
(2021).
83 Id. at 579.
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“extraordinary” relief.84 In addition to highlighting the fact that the pandemic
has only worsened in the months since the injunction was first ordered,
Justice Sotomayor called out the FDA’s inconsistent and flawed approach to
decision-making during the pandemic: “Government policy now permits
patients to receive prescriptions for powerful opioids without leaving home,
yet still requires women to travel to a doctor’s office to pick up mifepristone,
only to turn around, go home, and ingest it without supervision.”85 Abortion
advocates, including ACOG, have also derided the Court’s decision.86
What happens next? Several advocacy organizations are urging the
Biden Administration to suspend enforcement of the in-person requirements
for the duration of the pandemic.87 This would effectively reverse course on
the Supreme Court’s decision. In California, a suspension of enforcement
would allow patients to continue to access MAB via telehealth and mail-order
pharmacy.
C. Recommendation: California Should Foster Analysis of MAB
Data Collected While In-Person Requirements Were Lifted
For the brief period of July through December 2020, TeleMAB was a
reality for patients across California. Though it is still too soon to know how
many patients utilized these services, it is possible that there is significant
data to inform the State’s planning for MAB expansion, especially if the
REMS are permanently lifted. But regardless of the Administration’s
actions, many advocates feel as though “the cat is out of the bag” and that
TeleMAB will only continue to expand.88 In preparation for that reality, the
State of California has a unique opportunity to understand outcomes
associated with no-touch MAB and TeleMAB: the State should launch an
effort to centralize and analyze data surrounding MAB provision while the
REMS were lifted.
This would ideally be a repository where providers can share
comprehensive notes and data – clinic information (including geography and

84 Am. Coll. of Obstetricians & Gynecologists, 141 S. Ct. at 579 (Sotomayor, J.,
dissenting).
85 Id.
86 See, e.g., ACOG Action (@ACOGAction), T WITTER (Jan. 12, 2021, 5:16 PM),
https://twitter.com/ACOGAction/status/1349148168877969411?s=20.
87 Georgeanne M. Usova, The Supreme Court Let the Trump Administration Endanger
Abortion Patients During a Pandemic. The Biden-Harris Administration Can Fix It Right
Away., ACLU (Jan. 14, 2021), https://www.aclu.org/news/reproductive-freedom/thesupreme-court-let-the-trump-administration-endanger-abortion-patients-during-a-pandemicthe-biden-harris-administration-can-fix-it-right-away/.
88
Susan Rinkunas, A Bitter Pill, MARIE CLAIRE (Jan. 13, 2021),
https://www.marieclaire.com/politics/a35203155/pandemic-abortion-telemedicine.
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community demographics), patient demographics (age, race, income level,
language preferences), insurance information (particularly around Medi-Cal
reimbursement), health and safety outcomes, follow-up information,
anecdotal evidence, testimonials from patients and providers, challenges and
successes with different technology platforms, experiences with mail-order
infrastructure, and more. Several private and non-profit entities already
collect such data points, but there is no centralized effort across the state to
focus explicitly on COVID-19-era outcomes.89 After collection, the State can
assess the data and evaluate TeleMAB models based on specific factors such
as:90
• Accessibility of services and appointments relative to patient needs
• Ready supply of MAB relative to patient needs
• Use of technology platforms and accommodations made for patients
with disabilities, unstable internet connections, and limited devices
• Affordability of services
• Provider comfort level and satisfaction with remote counseling,
prescription, and dispensation of MAB
• Patient comfort level and satisfaction with remote counseling,
prescription, dispensation, and abortion procedure
• Medical outcomes and adverse drug experiences
This information, combined with data from the Department of Health
Care Services (DHCS) around changes in Medi-Cal reimbursements
discussed in the next section of this note, will empower California to
contribute to ongoing research on the promise of TeleMAB—with special
attention to low-income patients. After analysis, the State can share its
findings with those working to expand access at the federal and state levels,
bolstering the case for permanently removing the REMS restrictions and
building policy infrastructure for widely accessible TeleMAB. Months’
worth of insight can inform policy, guide providers and pharmacies, and
codify processes for a smooth transition into the future of reproductive health
care.
Opponents would argue that the State has competing priorities during the
COVID-19 public health emergency, and that California has limited
resources to direct at a time when the health and economic livelihoods of its
residents are at stake. This is a valid argument: data shows that California
89 Some of these institutions are cited in this note, including Planned Parenthood, Kaiser
Family Foundation, Ibis Reproductive Health, Guttmacher Institute, and Gynuity Health
Projects, in addition to researchers at various academic research centers like the University of
California, San Francisco’s Bixby Center for Global Reproductive Health.
90 Telehealth for Medication Abortion Delivery Models, IBIS REPRODUCTIVE HEALTH
(Oct. 2019) (these criteria suggestions are based off criteria developed by Ibis Reproductive
Health’s study of telehealth abortion models).

3- PINCHUK- HRPLJ V18-2 (DO NOT DELETE)

Summer 2021

4/7/2021 1:05 AM

CAL. POL’Y RECOMMENDATIONS FOR MEDICATION ABORTION

281

experienced massive spikes in infections and death from COVID-19—not to
mention the devastating impacts to its economy and the health and safety of
our most vulnerable residents.91 The death rate for Latino people is twentyone percent higher than the statewide average; the death rate for Black people
is six percent higher than statewide; the case rate for Pacific Islanders is
thirty-one percent higher than statewide; and the case rate for communities
with median income under $40,000 is thirty-eight percent higher than
statewide.92 A feasible alternative solution would be for the state to outsource
or corral organizations across the state that already collect similar data. This
solution would involve the aggregation and streamlining of that information
at the tail end of data collection. In 2016, nonprofit organization Gynuity
Health Projects launched a study on TeleMAB with the goal of proving its
safety and efficacy.93 Now running in thirteen states and the District of
Columbia, the study tracks pregnant patients who receive virtual counseling
with an abortion provider, go to any local facility to undergo any necessary
testing, and then receive mifepristone and misoprostol by mail.94 The State
could cut down on resource expenses by contracting with an organization like
Gynuity, which receives funding from a combination of research institutions,
foundations, and agencies.95
A likely obstacle to implementation would be hesitancy on the part of
providers to submit information about abortion provision. As previously
discussed, given the political nature of abortion and the prevalence of antiabortion violence, providers are often wary of submitting any identifying
information about themselves, their patients, and their practices, due to
privacy, confidentiality, and security concerns.96 One solution to mitigate
these concerns might be for the State to engage trusted, credible, and
respected physicians and experts to encourage provider participation. The
reproductive rights advocacy community in California is strong and tightknit; it is plausible that having a few key people on board early in the process
may create momentum for participation. Such a data collection program

91

Tracking COVID-19 in California, CA.GOV, https://covid19.ca.gov/state-dashboard/
(last visited Mar. 13, 2021). At the time of this writing, California has 3,523,563 confirmed
cases of COVID-19, resulting in 55,095 deaths.
92 California’s Commitment to Health Equity, CA.GOV, https://covid19.ca.gov/equity/
(last visited Mar. 16, 2021).
93
See
For
Providers
&
Allies,
GYNUITY
HEALTH
PROJECTS,
https://telabortion.org/about/for-providers (last visited Mar. 13, 2021).
94
TelAbortion, GYNUITY HEALTH PROJECTS, https://telabortion.org/_/assets/TelAbortionOne-pager-May-2020.pdf (last visited Mar. 13, 2021).
95 Donors, GYNUITY HEALTH PROJECTS, https://gynuity.org/donors (last visited Mar. 13,
2021).
96 Telephone Interview with Lisa Matsubara, General Counsel and Vice President of
Policy, Planned Parenthood Affiliates of California, on Nov. 25, 2020 (on file with author).
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would necessitate the strictest security, and all identifying information about
providers and patients would be stripped upon submission.

III.

INCREASING MEDICATION ABORTION ACCESS
UNDER MEDI-CAL

Public funding represents a significant obstacle for people seeking health
care across the country. This is especially true for abortion care, even in
California. Despite the State’s express commitment to reproductive rights,97
current requirements for Medi-Cal reimbursement can make MAB
inaccessible. This section discusses funding restrictions, how Medi-Cal
patients are affected, and why lifting the dual-ultrasound requirement is a
viable solution.
A. Federal Abortion Funding Restrictions
A patient’s right to obtain any method of abortion in the United States is
famously protected by the U.S. Constitution’s Fourteenth Amendment under
Roe v. Wade.98 But for millions of people of reproductive age across the
country, access to abortion is difficult. For low-income patients, patients in
abortion-hostile states, and patients in rural areas in particular, accessing
abortion care poses significant challenges.99 This is largely due to gaps in
funding and relentless efforts by state legislators to shut down abortion
clinics. As of March 2020, there were twenty-seven “abortion deserts” in the
United States, defined as regions where women have to travel more than 100
miles to access an abortion.100 Six states are down to just one clinic.101
Depending on location, gestation, and method, early-term abortion services
range in cost from $300 to about $1,700 and between $300 and $800 for
MAB.102,103 This does not include associated costs of transportation, missed
work wages, childcare, and lodging for patients who are forced to travel far
97 E.g., California Proclamation on Reproductive Freedom (May 31, 2019), available at
https://www.gov.ca.gov/wp-content/uploads/2019/05/Proclamation-on-ReproductiveFreedom.pdf.
98 Roe v. Wade, 410 U.S. 113 (1973).
99 Although Many U.S. Women of Reproductive Age Live Close to an Abortion Clinic, A
Substantial Minority Would Need to Travel Far to Access Services, GUTTMACHER INST. (Oct.
3,
2017),
https://www.guttmacher.org/news-release/2017/although-many-us-womenreproductive-age-live-close-abortion-clinic-substantial.
100
Jeltsen, supra note 65.
101 Id.
102 Charlotte Cowles, How Much Does an Abortion Cost? Learn the Facts., THE CUT
(Nov. 20, 2018), https://www.thecut.com/2018/11/how-much-does-an-abortion-cost.html.
103 How Much Does the Abortion Pill Cost?, CARAFEM, https://carafem.org/how-muchdoes-the-abortion-pill-cost/ (last visited Feb. 27, 2021).
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distances to clinics and must observe state-imposed waiting periods between
counseling and procedure.104
Just three years after the Roe decision enshrined the Constitutional right
to choose an abortion, Congress enacted the Hyde Amendment—a major
financial barrier to accessing abortion care.105 The Hyde Amendment bans
federal Medicaid funding for abortion services, except in cases where
continuing the pregnancy will endanger the life of the patient or when the
pregnancy results from rape or incest.106 It also restricts abortion funding
under the Indian Health Service, Medicare, and the Children’s Health
Insurance Program (CHIP).107 An estimated nineteen percent of women of
reproductive age in the United States rely on Medicaid.108 The Hyde
Amendment ensures that those patients pay out-of-pocket for abortion care.
The policy has withstood legal challenges, most famously in the 1980 case
of Harris v. McRae, which holds that states are not obligated to pay for
abortion care and that Hyde does not violate the Fifth Amendment nor the
Establishment Clause of the First Amendment.109 Though President Biden
has voiced support for ending the Hyde Amendment, its future remains
unclear as a majority of Congressional Republicans continue to embrace the
restriction.110
A 2019 regulation promulgated by the Department of Health and Human
Services represents a more recent effort to limit federal funding for
abortion.111 Known among abortion care advocates as the “domestic gag
rule,” the rule effectively forces programs that rely largely on federal Title X
funding to choose between receiving funds and providing abortion
services.112 Consequently, many programs, including Planned Parenthood—
104 Cowles, supra note 102; State Laws and Policies: Counseling and Waiting Periods
for Abortion, GUTTMACHER INST. (updated Mar. 1, 2021), https://www.guttmacher.org/statepolicy/explore/counseling-and-waiting-periods-abortion.
105 See Alina Salganicoff, Laurie Sobel & Amrutha Ramaswamy, The Hyde Amendment
and Coverage for Abortion Services, KAISER FAM. FOUND. (Jan. 2020),
http://files.kff.org/attachment/Issue-Brief-The-Hyde-Amendment-and-Coverage-forAbortion-Services; Hyde Amendment, Pub. L. No. 94-439 § 209, 90 Stat. 1418, 1434 (1976).
106 Id.
107 Id.
108 Id. at 2-3.
109 Harris v. McRae, 448 U.S. 297, 326 (1980).
110 Juliegrace Brufke, House Republicans vow not to support spending bills that repeal
Hyde
Amendment,
THE
HILL
(Jan.
26,
2021,
11:26
AM),
https://thehill.com/homenews/house/535863-house-republicans-vow-not-to-supportspending-bills-that-repeal-hyde-amendment.
111 Ruth Dawson, Trump Administration’s Domestic Gag Rule Has Slashed the Title X
Network’s
Capacity
by
Half,
GUTTMACHER
INST.
(Feb.
5,
2020),
https://www.guttmacher.org/article/2020/02/trump-administrations-domestic-gag-rule-hasslashed-title-x-networks-capacity-half.
112 Id.
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the largest network of family planning provision for low-income people in
country—have withdrawn from the Title X program altogether.113 Before the
domestic gag rule was instated, around 4,000 clinics received Title X
funding, serving approximately four million patients annually.114 It is
estimated that the rule has reduced the Title X network’s capacity by fortysix percent nationwide, and by much more in many states.115 California is
one of nine states in which Planned Parenthood served at least fifty percent
of contraceptive clients served at Title X–funded centers before the rule was
implemented.116
Within days of his inauguration, President Biden took steps to
“undo the damage” of these Trump Administration policies.117 Most notably,
the president signed an executive order rescinding the harmful global gag
rule, which prevented U.S.-funded organizations overseas from providing or
counseling for abortion services.118 During his campaign, the president
vowed to similarly reverse the domestic gag rule; as of the time of this
writing, the Administration has taken steps to “consider” revocation but the
rule is still in effect.119
B. The Myth of California as a Haven State
California affords greater protection of a patient’s right to choose an
abortion than does the U.S. Constitution. In 1969, California recognized the
right of procreative choice under the State Constitution.120 In 1972,
Californians amended the State Constitution to include an explicit protection
for privacy, which has been interpreted as protecting the right to choose

113 David Crary & Ricardo Alonso-Zaldivar, Planned Parenthood leaves federal family
planning
program,
ASSOCIATED
PRESS
(Aug.
19,
2019),
https://apnews.com/article/9e62021bcde04e69aa2ffc2e70a60f8f; see also The Irreplaceable
Role of Planned Parenthood Health Centers, PLANNED PARENTHOOD (Jan. 2019),
https://www.plannedparenthood.org/uploads/filer_public/33/63/3363814b-938e-4ad5-87d257ee98790766/190117-irreplaceable-role-pp-v01.pdf.
114 Dawson, supra note 111.
115 Id.
116 The State of California failed in its effort to enjoin the rule in California ex. rel.
Becerra v. Azar, 950 F.3d 1067 (9th Cir. 2020).
117 Ema O’Connor, Biden Just Repealed One of Trump’s Major Anti-Abortion Policies,
BUZZFEED NEWS (Jan. 28, 2021), https://www.buzzfeednews.com/article/emaoconnor/bidenexecutive-order-abortion-global-gag-rule-trump.
118
Id.
119 Id.
120 People v. Belous, 458 P.2d 194, 199 (Cal. 1969) (“[t]he fundamental right of the
woman to choose whether to bear children follows from the Supreme Court’s and this court’s
repeated acknowledgement of a ‘right of privacy’ or ‘liberty’ in matters related to marriage,
family, and sex.”).
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abortion.121 In 2002, the State legislature codified a statute guaranteeing that
“every woman has the fundamental right to choose to bear a child or to
choose and to obtain an abortion.”122 And in 2019, Governor Newsom issued
an executive “Proclamation on Reproductive Freedom”—a symbolic
commitment to the recognition and expansion of reproductive rights
including abortion.123 California is one of sixteen states to use its own
Medicaid dollars to cover abortion for low-income women for any reason.124
In addition, the State’s Family Planning Access Care Treatment (PACT)
program provides coverage for family planning services to uninsured women
up to two-hundred percent of the federal poverty level.125 All told, an
estimated twenty-six percent of California women of reproductive age rely
on Medicaid, and Medi-Cal covers about half of California abortions.126,127
This supportive policy environment, plus a massive expansion of MediCal under the Affordable Care Act, gives California the reputation of a haven
state for abortion provision. But the State is not immune to disparities in
access, particularly when it comes to low-income patients. The combination
of a limited number of providers in rural areas, barriers to patient enrollment,
and low Medi-Cal reimbursement rates significantly deter Medi-Cal-eligible
abortion patients from getting care. About forty percent of counties in
California do not have an abortion provider, and a 2011 study of low-income
women relying on Medicaid found that twelve percent traveled fifty-plus

121
CAL. CONST. art. I, § 1; Comm. to Defend Reproductive Rights v. Myers, 625 P.2d
779, 798 (Cal. 1981).
122 CAL. HEALTH & SAFETY C ODE § 123462.
123 California Proclamation on Reproductive Freedom (May 31, 2019), available at
https://www.gov.ca.gov/wp-content/uploads/2019/05/Proclamation-on-ReproductiveFreedom.pdf.
124 Alina Salganicoff, Laurie Sobel & Amrutha Ramaswamy, Coverage for Abortion
Services in Medicaid, Marketplace Plans and Private Plans, KAISER FAM. FOUND. (June 24,
2019),
https://www.kff.org/womens-health-policy/issue-brief/coverage-for-abortionservices-in-medicaid-marketplace-plans-and-private-plans/ [hereinafter KAISER, Coverage];
State Funding of Abortion Under Medicaid, GUTTMACHER INST. (Feb. 1, 2021),
https://www.guttmacher.org/state-policy/explore/state-funding-abortion-under-medicaid.
125 Family PACT, however, does not cover abortion services. Beyond the Numbers:
Access to Reproductive Health Care for Low-Income Women in Five Communities, KAISER
FAM. FOUND. (Nov. 14, 2019), https://www.kff.org/womens-health-policy/report/beyond-thenumbers-access-to-reproductive-health-care-for-low-income-women-in-five-communities/
[hereinafter KAISER, Beyond the Numbers].
126 KAISER, Coverage, supra note 124.
127 Nicole E. Johns, Diana Greene Foster & Ushma D. Upadhyay, Distance traveled for
Medicaid-covered abortion care in California, 17 BMC HEALTH SERV. RES. 287 (2017) (citing
CALIF. DEP’T OF HEALTH CARE SERVS., Medi-Cal funded induced abortions, 2010).
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miles to obtain a publicly funded abortion.128,129
A Kaiser Family Foundation case study of Tulare County, located in the
central region, illustrates the issue of access.130 One of the poorest counties
in California, Tulare has a host of challenges present in regions across the
State: extreme poverty, prevalence of domestic violence, and a significant
population of undocumented immigrants who face language barriers and/or
do not seek services out of fear of deportation.131 Women in Tulare County
cited transportation, cost, stigma, and “fear of family members finding out”
as major hurdles to accessing abortion.132 Those who do seek abortion care
must travel more than fifty miles to the nearest city of Fresno.133 Study
participants said that the community is conservative largely due to Roman
Catholic influence in the sixty-five percent Hispanic population, which leads
to resistance to abortion from both providers and patients.134 Considering
Tulare, it is no surprise that patients who rely on Medi-Cal across the State
have difficulty finding a provider where they live.
Further, misconceptions and misinformation about Medi-Cal eligibility
also affect enrollment in the Medi-Cal program.135 According to data and
anecdotal evidence, patients are sometimes incorrectly told that they need to
submit certain forms or information, such as citizenship documents, in order
to qualify for coverage.136 (In reality, citizenship documents are not
required.137) Again, these misconceptions lead to delayed care, pregnancyrelated complications, and carrying unwanted pregnancies to term.138
Finally, California’s low Medi-Cal reimbursement rates are an obstacle
to MAB access. In a multi-state study of barriers to Medicaid acceptance for
all methods of abortion, providers cited low reimbursement rates as the

128

Rachel K. Jones, Elizabeth Witwer & Jenna Jerman, Abortion Incidence and Service
Availability in the United States, 2017, GUTTMACHER INST. (Sept. 2019),
https://www.guttmacher.org/report/abortion-incidence-service-availability-us-2017.
129 Nicole E. Johns, Diana Greene Foster & Ushma D. Upadhyay, Distance traveled for
Medicaid-covered abortion care in California, 17 BMC HEALTH SERV. RES. 287 (2017).
130 KAISER, Beyond the Numbers, supra note 125.
131 Id.
132 Id.
133 Id.
134 Id.
135 Barriers to abortion care in California: Highlighting challenges of Medi-Cal
Coverage, ACCESS WOMEN’S HEALTH JUST., IBIS REPRODUCTIVE HEALTH & ALL ABOVE ALL
(Sept.
2016),
https://ibisreproductivehealth.org/sites/default/files/files/publications/Brief%20MediCal%20
coverage.pdf.
136 Id.
137 Id.
138 Id.
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primary barrier.139 While reimbursement rates and costs of services vary,
California has one of the lowest average Medicaid reimbursement rates for
physicians in the country.140 This was exacerbated in 2015 with the passage
of AB 97, which enacted a ten percent reduction in reimbursement rates for
most fee-for-service Medi-Cal providers.141 Low reimbursement rates for
abortion services can result in steep out-of-pocket costs for patients; fewer
providers who accept federal insurance coverage due to lack of
reimbursement or process hassles that outweigh the benefits of receiving such
low payments; and, clinic closures or reductions in staff due to significant
losses on un-reimbursed services.142
When seeking Medi-Cal reimbursement specifically for MAB, providers
receive a bundled payment for services rendered over a fourteen-to-eighteenday period and include all office visits, pelvic ultrasounds, laboratory studies,
urine pregnancy tests, and patient counseling.143 One of the costliest pieces
of the bundled payment requirements is the pelvic ultrasound. To be eligible
for reimbursement, MAB patients in California are required to receive two
in-office ultrasounds: the first to determine gestational age of the pregnancy
before MAB, and the second, performed after the pill regimen, to ensure
termination is complete.144 The cost of a pregnancy ultrasound typically
ranges from $200 to $300 but can be significantly more (the Healthcare
Bluebook estimates a “fair” price at $225, though this does not correspond to
reimbursement rates for ultrasounds in the in the Medi-Cal fee schedule).145
According to data from DHCS, in 2014 the average reimbursement rate for
fee-for-service, Medi-Cal-funded MAB provision service was $561.146 Thus,
139
Amanda Dennis & Kelly Blanchard, Abortion Providers’ Experiences with Medicaid
Abortion Coverage Policies: A Qualitative Multistate Study, 48 HEALTH SERV. RES. 1, 236-52
(2013).
140 HHS Administrative Complaint: Inadequate Access to Health Care Violates Latino
Civil Rights in California’s Medi-Cal Program, NAT’L HEALTH LAW PROGRAM (Dec. 15,
2015),
https://healthlaw.org/resource/hhs-administrative-complaint-inadequate-access-tohealth-care-violates-latino-civil-rights/.
141 Assembly Bill 97 Ten Percent Pharmacy Payment Reductions, C ALIF. DEP’T OF
HEALTH
CARE
SERVS.,
https://www.dhcs.ca.gov/provgovpart/pharmacy/Pages/AB97Main.aspx (last modified Sept.
10, 2019, 2:41 PM).
142 Dennis & Blanchard, supra note 139.
143 Medi-Cal Provider Manual, supra note 33.
144 Id.
145 Ruthie Dean, Expecting? How Much Does an Ultrasound Cost?, BERNARD BENEFITS
(Oct. 14, 2020), https://blog.bernardbenefits.com/expecting-how-much-does-an-ultrasoundcost.
146 Reimbursement for early pregnancy surgical abortions in 2014 averaged $438. This
price differential can be attributed to the costs of pills and to the two-ultrasound requirement
for MAB. CALIF. DEP’T OF HEALTH CARE SERVS., RSCH. & ANALYTIC STUDIES DIV., Medi-CalFunded
Induced
Abortions,
2014
(Oct.
2016),
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after covering costs of the ultrasounds, that leaves just a little over $100 to
cover the cost of pills, pregnancy and lab tests, plus all remaining staff, office,
and administrative costs.
Additionally, it is not uncommon for MAB patients to skip the follow-up
appointment and the second ultrasound for logistical or personal reasons,
including the inability to take off work, lack of childcare, and the emotional
stress of returning to a clinic.147 In these instances, which are uniquely out
of providers’ control, providers must use a modifier on their billing that drops
reimbursement down by almost fifty percent—a sizable decrease in
reimbursement despite the fact that all other costs of provision remain the
same.148 Thus, for many safety-net providers who primarily serve lowincome patients, the significant decrease in the reimbursement rate brought
about by the modifier makes it is financially difficult to accept Medi-Cal
insurance for MAB.
C. Recommendation: California
Ultrasounds
from
MAB
Requirements

Should Eliminate Pelvic
Medi-Cal
Reimbursement

Following the July 2020 federal injunction on the FDA REMS for
mifepristone, DHCS issued a directive temporarily relaxing requirements for
MAB reimbursement under Medi-Cal.149 DHCS lifted both enforcement of
the FDA’s in-person requirements and the ultrasound requirement from the
bundled payment option coded as S0191:
Providers who bill using HCPCS code S0191 to prescribe
mifepristone to end early pregnancies, may provide
medically necessary services without an in-person visit or
signature … Further, DHCS is revising the Abortion (abort)
section of the Provider Manual to ensure flexibilities exist for
providing medically necessary abortion services during the
COVID-19 public health emergency and to remove
requirements for a Medicare denial for certain abortion
services.150

https://www.dhcs.ca.gov/dataandstats/statistics/Documents/Medi-Cal-Funded-Abortions2014.pdf.
147
Matsubara, supra note 96.
148 Id.
149 Important News about Women’s Health Services, CALIF. DEP’T OF HEALTH CARE
SERVS.
(July
29,
2020),
https://files.medical.ca.gov/pubsdoco/newsroom/newsroom_30339_77.aspx.
150 Id. (emphases added).
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Permanently eliminating the requirements for ultrasounds for Medi-Cal
reimbursement, and rather allowing providers the flexibilities to provide
appropriate MAB care based on patient needs and desires, would be a huge
win for providers and patients. Not only is the dual ultrasound requirement
costly, but it is not medically necessary for patient safety and procedural
efficacy.151
The three primary goals of a clinical evaluation before MAB are to
confirm that the gestational age is within accepted limits for safe and
effective outpatient treatment, to identify ectopic pregnancy, and to establish
that the patient has no contraindications to mifepristone or misoprostol. 152
Historically, an ultrasound is used during clinical evaluation because it was
thought to be the best way to determine gestational age of a pregnancy—but
it is not the only way to do so: as previously discussed, a no-touch protocol
utilizing patient-reported information about last menstrual period (LMP) can
help clinicians date gestational age of a pregnancy to an extremely high
degree of accuracy.153 In fact, a prospective study conducted in 2015-2016
in the United States, Mexico, and Moldova provided 406 medication
abortions without ultrasound or pelvic examination, and no reported serious
adverse events were connected to these omissions.154 The National Abortion
Federation’s clinical policy guidelines state that “the use of ultrasound is not
a requirement for the provision of first-trimester abortion care”; rather, “use
of ultrasound may inform clinical decision-making.”155 The FDA does not
require ultrasounds as part of the REMS for mifepristone. In fact, the
Medication Guide for Mifeprex does not require an ultrasound but says that
a provider “may do a clinical examination, an ultrasound examination, or
other testing to determine how far along [the patient is] in pregnancy.”156
The second primary goal of the traditional clinical evaluation before
MAB is to identify ectopic pregnancy, a serious condition that occurs when
a fertilized egg attaches itself not to the uterus but to a fallopian tube,
abdominal cavity, or cervix.157 Similar to LMP dating, ectopic pregnancies
151

Raymond et al., supra note 72.
Id.
153 Hillary Bracken et al., Alternatives to routine ultrasound for eligibility assessment
prior to early termination of pregnancy with mifepristone–misoprostol., 118 BJOG 17, 17-23
(2011).
154 For more than 15 years, international organizations have provided tens of thousands
of patients with MAB medications by mail, after screening them only by history. Raymond et
al., supra note 72.
155
2020 Clinical Policy Guidelines for Abortion Care, NAT’L ABORTION FED’N,
https://5aa1b2xfmfh2e2mk03kk8rsx-wpengine.netdna-ssl.com/wpcontent/uploads/2020_CPGs.pdf (last visited Feb. 28, 2021) (emphasis added).
156
Medication
Guide:
Mifeprex,
U.S.
FOOD
&
DRUG
ADMIN.,
https://www.fda.gov/media/72923/download (last visited Feb. 28, 2021).
157 Raymond et al., supra note 72.
152
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can be identified through patient-reported information regarding recent
vaginal bleeding, pelvic pain or cramping, medical history of pelvic
inflammatory disease, or presence of an intrauterine device at conception.158
While it must be noted that many patients with ectopic pregnancies will
exhibit no risk factors, data suggests that the incidence of ectopic pregnancy
among patients seeking MAB is less than one percent.159 Further, the
condition can be determined post-MAB through other means like take-home
pregnancy testing.160
In terms of the third goal of identifying contraindications to the
medication, clinicians can use specific questions about medical history and
symptoms, typical of routine medication screening, to determine whether a
patient is at risk before prescribing.161
The follow-up ultrasound requirement after MAB is similarly medically
unnecessary. The primary goals of the follow-up are to confirm termination
of pregnancy, to detect ectopic pregnancies that were previously
undiagnosed, and to identify any complications in need of treatment. 162
Patient-reported information about symptoms can be used in conjunction
with high-sensitivity pregnancy tests to accomplish these goals, bypassing
the need for an ultrasound.163 (For example, a pregnancy test showing
positive post-MAB could suggest presence of an ectopic pregnancy.)
Moreover, as previously mentioned, patients are often “lost to follow-up,”
i.e. they do not present in-office after completing the pill regimen.164
ACOG’s most recent guidelines state that routine in-person follow-ups with
an ultrasound are not necessary after an uncomplicated medication
abortion.165 Some clinicians have even offered patients the option to conduct
a follow-up appointment by telephone or video as a more convenient and less
emotionally taxing alternative to presenting in-office.166
A relaxation of the ultrasound requirement could catalyze a domino
effect of positive change. Once data from California MAB providers using
no-touch protocols is analyzed, it will likely underscore the conclusion that
158

Raymond et al., supra note 72.
Id.
160 Id.
161 Id.
162 Id.
163 Id.
164 See, e.g., Medication Abortion Up to 70 Days Gestation, ACOG Practice Bulletin
(Oct.
2020),
https://www.acog.org/-/media/project/acog/acogorg/clinical/files/practicebulletin/articles/2020/10/medication-abortion-up-to-70-days-gestation.pdf.
165 Id.
166 A study found that offering alternative follow-up options to in-person visits, such as
telephone or video conferences, may decrease the proportion of women who are lost to followups. Melissa J. Chen et al., Comparing office and telephone follow-up after medical abortion,
94 CONTRACEPTION 122, 122-26 (2016).
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ultrasounds are not necessary to ensure safe and effective MAB provision.
This could reinforce the case for permanent elimination of the ultrasound
requirements for Medi-Cal reimbursement, leading to higher reimbursements
for MAB, an increase in the number and geographic distribution of providers
accepting Medi-Cal for MAB, and broadened access for Californians who
need it most—those who rely on Medi-Cal and those who live in areas far
from clinics and hospitals.

IV. TELEHEALTH MEDICATION
MINOR CONSENT

ABORTION

AND

As telehealth for MAB becomes more viable, a specific patient
population is currently being overlooked in California: minors. Minors in
California do not need parental involvement to access MAB, but they may
not be able to receive telehealth services without parental consent.167 This
statutory mismatch creates a paradox wherein a minor can consent to a
treatment, but not to the modality of its prescription. Because telehealth
consent requirements have been temporarily suspended in California under
Executive Order by the governor, this is unlikely to become an urgent issue
for the duration of the COVID-19 public health emergency.168 However, this
loophole may effectively prevent some minors from accessing MAB via
telehealth in the future. As the State looks ahead to a future with fewer
restrictions on MAB, it is critical to address this issue.
A. The Minor-TeleMAB Paradox
Under section 123450 of the California Health and Safety Code, minors
may not obtain abortion care without parental consent.169 But in the 1997
case of American Academy of Pediatrics v. Lungren, the California Supreme
Court found this statute in violation of the California Constitution.170 The
court held that a parental consent statute “impinges upon a fundamental
autonomy privacy interest” and “denies a pregnant minor, who believes it is
in her best interest to terminate her pregnancy rather than have a child at such
a young age, control over her own destiny.”171 The court reasoned that the
statute most significantly impacted pregnant minors who were “too
frightened or too embarrassed to disclose her condition to a parent (or to a
167

Am. Acad. of Pediatrics v. Lungren, 940 P.2d 797 (Cal. 1997).
Calif. Exec. Order No. N-43-20 (Apr. 3, 2020), https://www.gov.ca.gov/wpcontent/uploads/2020/04/4.3.20-EO- N-43-20-text.pdf.
169 CAL. HEALTH & SAFETY C ODE § 123450.
170 Am. Acad. of Pediatrics v. Lungren, 940 P.2d 797 (Cal. 1997).
171 Id. at 338-39.
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court).”172 Unlike thirty-seven other states, California does not require
parental involvement or judicial authorization for a minor to obtain an
abortion.173
Because California does not restrict provision of MAB via telehealth,
logic dictates that a pregnant minor should be able to legally access TeleMAB
services.174 However, the U.S. Constitution protects the right of parents to
consent to the medical treatment of their children.175 A violation of that right
has been found relevant under both the Fourth Amendment and the due
process clause of the Fourteenth Amendment.176 While the U.S. Supreme
Court has not defined the exact scope of a parent’s right to direct their child’s
medical care, the Court has consistently acknowledged—and upheld—the
existence of that parental right.177 In California, a minor may not consent to
medical care unless the minor is fifteen years old, lives “separate and apart”
from parents or guardians, and manages their own finances.178
Today, the State permits the use of telehealth for most service provision
as long as it is performed by a California licensed physician and complies
with state and federal privacy laws.179 Under section 2290.5 of the Business
and Professions Code, a patient must give verbal or written consent to
telehealth as a modality of care.180 However, unlike the State’s laws allowing
minors to consent to certain sensitive services like abortion as mentioned
above, no language exempts the telehealth consent requirement for minors
seeking virtual care. Therefore, minors seeking telehealth services for MAB
likely still require parental consent.181
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Lungren, 940 P.2d at 314.
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Minors’
Abortions,
GUTTMACHER
INST.,
https://www.guttmacher.org/state-policy/explore/parental-involvement-minors-abortions
(last visited Feb. 28, 2021).
174 See, e.g., Jeltsen, supra note 65 (discussing the solution telemedicine can provide).
175 Troxel v. Granville, 530 U.S. 57, 66 (2000).
176 Dubbs v. Head Start, Inc., 336 F.3d 1194, 1222 (10th Cir. 2003).
177 Emily G. Narum, Making the Grade: School-Based Telemedicine and Parental
Consent, 53 SAN DIEGO L. REV. 745, 753 (2016).
178 CAL. FAM. CODE § 6922.
179 Practicing Medicine Through Telehealth Technology, MED. BD. OF CAL.,
https://www.mbc.ca.gov/Licensees/Telehealth.aspx (last visited Feb. 28, 2021).
180 CAL. BUS. & PROF. CODE § 2290.5. (“Before the delivery of health care via telehealth,
the health care provider initiating the use of telehealth shall inform the patient about the use
of telehealth and obtain verbal or written consent from the patient for the use of telehealth as
an acceptable mode of delivering health care services and public health. The consent shall be
documented.”).
181 For an example of written confirmation of parental consent to telehealth for their
minor
child,
see
this
form
from
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Clinical
Associates:
https://static1.squarespace.com/static/54650b6ee4b0788b699fe06a/t/5e70e5286a26061dbb4
06a3d/1584457001997/Telehealth+Consent+-+Minor+%28COVID-19%29.pdf.
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B. Recommendation: California Should Close the Loophole and
Permit Minor Consent to Telehealth Services for MAB
It is easy to see how this dissonance may be the result of simple oversight,
but it is one that should be corrected. Minors are a unique patient population
in that they tend to lack autonomy and control over their life situations and
are therefore particularly susceptible to delays in abortion care—especially
those who do not live near a clinic or hospital, do not have money or means
of travel, or are too frightened to tell their parents. Thus, it is especially
important that State policies do not obstruct minors from accessing safe, legal
abortion care in addition to other services that they can legally consent to
without parental involvement. California can ensure minors’ rights to obtain
an abortion by allowing minors to consent to telehealth provision of MAB
without parental consent. A solution should ensure that the State’s telehealth
consent requirements align with existing laws that allow minors to consent
to certain health care services.
This clarification could take the form of an amendment to State telehealth
policy, which is dictated by the Telemedicine Development Act of 1996, the
Telehealth Advancement Act of 2011, and several subsequent statutes
enacted by the legislature.182 Such an amendment would have substantial
grounding in the Lungren case, which specifically gives credence to
aforementioned concerns about privacy, safety, and infringement on personal
autonomy.183 The State should act to mitigate this complication before the
end of the public health emergency, at which time mandatory consent for
telehealth will be reinstated.
A counterargument to closing this loophole would be a slippery slope
concern: if minors can provide their own consent for telehealth services, then
soon enough parents will be completely bypassed in decisions about their
children’s medical care. This argument is a fallacy. No compelling evidence
suggests that Lungren has led to significantly less parental involvement in
their children’s medical care; therefore, there is no reason to expect that the
case would be different for telehealth for MAB. Minors should be able to
access services they can legally consent to without parental involvement—
regardless of the modality by which they receive that care.

182 CAL. BUS. & PROF. CODE § 2060; California Policy: Telehealth Advancement Act, CTR.

CONNECTED HEALTH POL’Y, https://www.cchpca.org/telehealth-policy/telehealthadvancement-act (last visited Feb. 28, 2021).
183 Lungren, 940 P.2d at 800.
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V. CONCLUSION
“As goes California, so goes the nation.”184 Californians take pride in
pioneering and influencing innovative policy on a range of issues, from
environmental conservation to cutting-edge technology. While it is true that
California is at the forefront of progress in reproductive rights, there is much
more we can do to expand access to Californians—and to continue to push
the rest of the country forward.
Medication abortion is safe, effective, and, as evidenced by current
conditions, has unique power to reach low-income and rural patients. By
supporting the collection of no-touch and TeleMAB data during the COVID19 public health emergency, revisiting the ultrasound requirements for MediCal reimbursement, and closing the loophole preventing minors from
accessing TeleMAB, California can lean into its role as a reproductive
freedom state. These are feasible solutions that align with the State’s
commitment to reproductive justice for all.

184 This common political maxim, here referring to California policy innovation, can be
traced to the state of Maine, which once served as a bellwether for U.S. presidential elections.
Andrew Glass, ‘As Maine goes, so goes the nation,’ Sept. 8, 1958, POLITICO (Sept. 8, 2016),
https://www.politico.com/story/2016/09/as-maine-goes-so-goes-the-nation-sept-8-1958227727.

